Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €3.55 EUR
Change Today -0.07 / -1.93%
Volume 12.6K
ALTER On Other Exchanges
EN Paris
As of 11:35 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

theradiag (ALTER) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/2/14 - €5.80
52 Week Low
12/16/14 - €3.33
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for THERADIAG (ALTER)

Related News

No related news articles were found.

theradiag (ALTER) Related Businessweek News

No Related Businessweek News Found

theradiag (ALTER) Details

Theradiag SA develops, produces, and markets in vitro diagnostics products in France and internationally. It offers auto-immunity products, such as FIDIS kits that allow detection of multiple analytes from the same sample in a single assay; immunofluorescence tests to screen and identify the auto-antibodies; ELISA tests for performing various tests on the same plate; Chorus systems that are compact multi-parametric analyzers; and immunoblot tests, which allow simultaneous detection of antibodies. The company also provides genetic tests comprising AmplideX products line for the diagnosis of the Fragile X syndrome; xTAG Gastrointestinal Pathogens Panel kits for identifying various gastrointestinal pathogens; xTAG Respiratory Viral Panel kits for identification of common respiratory viruses; and BCR/ABL1 Quant tests that are in vitro diagnostic products, as well as Signature kits. In addition, it offers CLA Optigen 30, an in vitro test for the diagnosis of allergy conditions; a panel of reagents for identifying the type of infectious diseases, such as bacteriology, virology, and parasitology; and Immunochromatographic rapid tests for the detection of drugs. Further, the company provides SQA-V system, a semen analyzer; V-Sperm for loading results, pictures, and videos to the computer; OCTEIA 25-Hydroxy Vitamin D kit intended to assay 25-Hydroxy vitamin D and other hydroxylated metabolites present in human serum or plasma; and Serum CrossLaps ELISA kits for the immunoenzyme assay of a specific C-terminal sequence for type I collagen in human serum and plasma, as well as CER F 820001F for analyzing small amounts of hemoglobin in feces. Additionally, it offers a range of instruments, including CARIS, e-Robot, FIDIS, and Chorus instruments for diagnosing auto-immunity and infectious diseases. The company also offers Lisa-Tracker kits for monitoring the treatment of patients treated by anti-TNFa. The company was founded in 1986 and is based in Marne-la-Vallée, France.

70 Employees
Last Reported Date: 03/4/15
Founded in 1986

theradiag (ALTER) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: €328.8K
Compensation as of Fiscal Year 2013.

theradiag (ALTER) Key Developments

Theradiag Announces New Marne-La-Valle Facility

Theradiag announced that it has moved into its new Marne-La-Valle facility, in the Paris area. The company's new location offers over 3,200 square meters of R&D and production laboratories, and office space. This represents a 60% gain in floor space with no significant increase in rental costs. Two thirds of the increase in space is allocated to R&D and production facilities, which will allow the Company to increase the volume of production and automation of its proprietary products.

TheraDiag SA Presents at CF&B European Small Cap Event, Apr-27-2015

TheraDiag SA Presents at CF&B European Small Cap Event, Apr-27-2015 . Venue: Paris, France.

TheraDiag SA Reports Consolidated Earnings Results for the Year Ended December 31, 2014

TheraDiag SA reported consolidated earnings results for the year ended December 31, 2014. For the year, revenues were EUR 7,113,000 against EUR 6,741,000 a year ago. Operating loss was EUR 3,193,000 against EUR 2,710,000 a year ago. Pre-tax loss was EUR 3,260,000 against EUR 2,754,000 a year ago. Net loss was EUR 2,964,000 against EUR 2,469,000 a year ago. The decrease in distribution revenues, anticipated as part of the company’s strategic reorientation, is more than offset by the sales of internal products.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALTER:FP €3.55 EUR -0.07

ALTER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALTER.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALTER Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERADIAG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at